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Molecular Pathogenesis of Oral 
Squamous Cell Carcinoma
Anshi Jain
Abstract
Oral carcinogenesis is a molecular and histological multistage process featuring 
genetic and phenotypic molecular markers which involves enhanced function of sev-
eral protooncogenes, oncogenes and/or the deactivation of tumor suppressor genes, 
resulting in the over activity of growth factors and its cell surface receptors, which 
could enhance messenger signaling intracellularly, and/or leads to the increased 
production of transcription factors. Alone oncogenes are not responsible for carcino-
genesis, genes having tumor suppressor activity, leads to a phenotypic change in cell 
which is responsible for increased cell proliferation, loss of cellular cohesion, and the 
ability to infiltrate local tissue and spread to distant sites. Understanding the molecu-
lar interplay of both onco and tumor genes will allow more accurate diagnosis and 
assessment of prognosis, which might lead the way for novel approaches to treatment.
Keywords: carcinogenesis, protooncogene, oncogene, tumor suppressor gene, 
intercellular signaling, cell surface receptors, growth factors
1. Introduction
According to the literature and current scenario it’s a well-known fact that 
environmental and genetic factors modulate the multistep process of carcinogen-
esis. Genetic events lead to the disruption of normal regulatory mechanism that 
control basic cellular function of the body including cell division, differentiation 
and cell death [1]. Boyd and Reade (1988) described the mechanisms involved in 
carcinogenesis of the oral mucosa and distinguished between three major groups: 
chemical mechanisms, physical mechanisms, and viral mechanisms. Later Hanahan 
and Weinberg (2000) described six hallmarks of cancer (hallmarks I): acquisition 
of growth signaling autonomy (oncogenes), growth-inhibitory signals (tumor 
suppressor genes), evasion of apoptosis, cellular immortalization, angiogenesis, 
and finally, invasion and metastasis [2]. A decade later, an updating review 
(henceforth termed hallmarks II) added two emerging hallmarks: reprogramming 
energy metabolism and evading immune response, and two enabling traits: genome 
instability and mutation, and tumor-promoting inflammation [3].
Oral squamous carcinogenesis is the sixth most common cancer worldwide and 
commonest cancer in India, accounting for 50–70% of total cancer mortality rate. 
It predominantly affects anterior tongue, cheek, floor of mouth, retro molar area, 
gingiva or the buccal mucosa [4]. In carcinogenesis multiple genetic events alter 
the normal functions of both oncogenes and tumor suppressor genes. However, the 
importance of both the known gene alterations is unidentified and is still not fully 
understood. The histologic progression of oral carcinogenesis from hyperplasia to 
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dysplasia, followed by severe dysplasia and eventual invasion and metastases, are 
believed to reflect the accumulation of these changes [5, 6] (Figure 1). Genetic 
alterations occurring during the carcinogenesis may present in the form of point 
mutations, amplifications, rearrangements, and deletions [5].
2. The genetic theory of cancer
2.1 Alteration of regulatory pathways during cancer development
Oral carcinogenesis is a complex, multistep process in which genetic events 
within signal transduction pathways governing normal cellular physiology are 
quantitatively or qualitatively altered.
Under normal conditions, cell biology of oral epithelia is tightly controlled by 
excitatory and inhibitory pathways which include cell division, differentiation, 
and senescence [1]. Cellular pathways of the oral keratinocyte may be diverse and 
contain the same fundamental elements. Binding of an extracellular ligand to a 
cell surface receptor forms a receptor-ligand complex that generates excitatory or 
inhibitory signals which are transferred intracellularly and further nuclear messen-
gers can either directly alter cell function or can stimulate the transcription of genes 
which can affect protein synthesis [1] (Figure 2).
On contrary, oral cancer is the result of an accumulation of changes in these 
excitatory and inhibitory cellular signals that can occur at any level of a given path-
way. Oral epithelial cells collect these alterations or mutations from cellular signals 
and become functionally independent from the surrounding oral epithelium made 
up of normal oral keratinocyte neighbors. These tumor cell divide more rapidly, 
sequester blood vessels to feed that growth, delete or amplify signals to produce 
abnormal structural or functional changes, and start invading normal tissue at local 
or distant sites [6].
Oncogenes and tumor suppressor genes constitute the cellular growth-regula-
tory genes which are widely expressed in normal cells and their protein products 
are required for cell to work normally. Any alteration or inappropriate expression of 
these genes can induce neoplasia [7].
The genetic damage of these genes found in cancer cells is of two sorts:
1. Dominant type: proto-oncogenes and oncogenes.
2. Recessive type: tumor suppressor genes, growth suppressor genes, recessive 
oncogenes, or anti-oncogenes.
The Former typically results in a gain of function, whereas latter causes loss of 
function [8].
The hallmark of cancer is rapid and uncontrolled growth. Cell cycle regulatory 
molecules (cyclin-CDK complex and retinoblastoma protein RB) play a key role 
Figure 1. 
Molecular model of oral carcinogenesis. The diagram shows the genetic progression from dysplasia to oral 
squamous cell carcinoma (OSCC), through changes in the p or q arm of chromosomes 3, 4, 8, 9, 11, 13, and 17 [2].
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in pathogenesis of head and neck cancers. Phosphorylation of RB by the cyclin/
CDK there is a release of E2F, which transcribe the necessary components of the 
cell to continue through the G1/S transition. Specifically, RB function is medi-
ated by cyclin E/CDK2 activity. In contrast, CDK4 and CDK6 act upstream of RB 
and inhibit RB function by phosphorylation [5]. In head and Neck cancers, both 
up and down regulation of RB function has been observed conferring a greater 
degree of malignancy and aggressiveness, dependent upon cellular context. 
Downregulation of RB function—cell cycle to remain unchecked and leads to 
continual cell division and cell proliferation; up-regulation of RB leading to a 
decrease in pro-apoptotic signals that are triggered during the cell cycle. In either 
case, changes in the RB pathway alter cell-cycle transition and allow for greater 
cancer cell survival [1].
3. Oncogenes and oncoprotein
Oncogenes can be classified according to the roles of their normal counterparts 
(protooncogenes) in the biochemical pathways that regulate growth and differen-
tiation. These include the following
1. Growth factors (TGF, FGF, PDGF)
2. Cell surface receptors (EGFR, FGFR)
3. Intracellular signal transduction pathways (RAS)
Figure 2. 
Signal—transduction pathway.
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4. DNA binding nuclear proteins transcription factors (MYC, FOS, JUN)
5. Cell cycle proteins (cyclins and cyclin dependent protein kinases)
6. Inhibitors of apoptosis (bcl-2)
Oncogenes are defined as “altered growth-promoting regulatory genes, or 
proto-oncogenes that govern the cell’s signal transduction pathways” [5]. These 
genes were initially discovered in retroviruses which cause cancers in birds 
and cats by virtue of a highly tumorigenic ‘molecular hitchhiker’, a mutated 
gene (oncogene) not native to the virus but picked up from a homologue 
in the eukaryotic genome. Alteration or mutation of these proto-oncogenes 
results in either an overproduction or a “gain-of-function” alteration in these 
excitatory proteins. Although oncogenes alone are not sufficient to trans-
form a normal oral keratinocyte to a malignant one, they are initiators of 
the process [6].
Aberrant expression of several oncogenes play a crucial role in development of 
oral carcinogenesis which includes proto-oncogene epidermal growth factor recep-
tor (EGFR/c-erb 1), members of the ras gene family, c-myc, int-2, hst-1, PRAD-1, 
and bcl-1 (Figure 3) [6].
The potential of proto-oncogenes to participate in tumorigenesis arises from the 
fact that their protein products are relays in the elaborate biochemical circuitry that 
governs the phenotype of vertebrate cells polypeptide hormones that act on the 
surface of the cell, receptors for these hormones, proteins convey signals from  
the receptors to the deeper cell machinery, and nuclear functions that orches-
trate the genetic response to afferent commands [5].
Three biochemical mechanisms which proto-oncogenes act are [8]:
1. The first mechanism is phosphorylation of proteins, with serine, threonine, 
and tyrosine as substrates.
2. The second mechanism by which the genes act is transmission of signals 
by GTPases. The role of these signaling devices in tumorigenesis was first 
Figure 3. 
Oral cancer progression model. The histopathologic progression of normal oral mucosa from hyperplasia 
to malignancy and metastasis appears driven by interplay of activation of oncogenes in early cellular 
transformation and inactivation of tumor suppressor genes closer to the initiation of malignancy and 
metastasis.
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appreciated through the discovery of RAS oncogenes, which encode a previ-
ously unknown variety of GTPase.
3. The third mechanism consists of control of transcription from DNA. A still 
growing variety of transcription factors (FOS and MYC) are encoded by proto-
oncogenes which may also participate directly in the replication of DNA.
3.1 Growth factor receptors and mechanisms
Activation of growth factor receptors in human tumors include mutations, gene 
rearrangements, and overexpression. Signaling pathways involved in the develop-
ment of both cancer and stem cells are: the JAK/STAT pathway, NOTCH signaling 
pathway, the MAP-Kinase/ERK pathway, the PI3K/AKT pathway, the NFkB path-
way, the Wnt pathway and the TGFβ pathways.
In the normal forms of growth factor receptors, the kinase is transiently acti-
vated by binding of the growth factors ligand to receptor, leads to rapid receptor 
dimerization and tyrosine phosphorylation of several substrates that are a part of 
the signaling cascade. The oncogenic growth factor receptors cause dimerization 
and activation without binding to the specific growth factor ligand. Hence, the 
mutant receptors deliver continuous mitogenic signals to the cell [1].
In oral carcinogenesis deregulation of growth factors receptors occurs through 
increased production and autocrine stimulation. Aberrant expression of trans-
forming growth factor alpha (TGF-α) and beta (TGF-β) occur in carcinogenesis. 
TGF-α work in association with EGFR and TGF-β follows a pathway along with 
SMAD2 and 3.
TGF-α is reported to occur early in oral carcinogenesis, following the histologi-
cal progression of hyperplastic epithelium first, and later in the invasive carcinoma 
within the inflammatory cell infiltrate, especially the eosinophils, surrounding the 
infiltrating epithelium. TGF-α stimulates cell proliferation by binding to EGFR and 
stimulates angiogenesis and has been reported to be found in “normal” oral mucosa 
in patients who subsequently develop a second primary carcinoma.
Microscopically “normal” oral mucosa of head and neck cancer patients who 
later develop second primary carcinomas overexpresses TGF-α suggesting a ‘prema-
lignant” lesion having rapid proliferation and genetic instability of the epithelium. 
Prognostically patients with oral tumors overexpressing TGF-α along with EGFR 
have been shown to have a significantly shorter survival than patients overexpress-
ing EGFR alone [6].
TGFβ1 signals through the TGFβ receptors and these transduce the signal by 
phosphorylating SMAD2 and SMAD3, which, together with SMAD4, regulate the 
transcription of target genes.
Recently, a connection of TGFβ signalling pathway and nuclear factor-κB 
(NF-κB)99 has been studied, it’s a transcription factor that provides an important 
survival signal to cells. Cohen et al. showed that abrogation of the TGF-β pathway 
was associated with activation of NF-κB, and this intriguing finding suggests that 
decreased TGFβ signalling is linked to NF-κB activation [9].
3.2 Cell surface receptors
Binding of cell surface receptor with ligands translates signals which are present 
extracellularly through the cell membrane by activating a cascade of biochemical 
reactions. Mutations or amplifications of genes encoding growth factor receptors 
can result in an increased number of receptors or production of continuous ligand-
independent mitogenic signals.
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EGFR, a 170,000-Da phosphoglycoprotein, is believed to be an important onco-
protein in oral cancer. Currently, three mechanisms have been postulated to activate 
the EGFR gene in carcinogenesis:
1. Deletion or mutations in the N-terminal ligand-binding domain.
2. Overexpression of the EGFR gene concurrent with the continuous presence of 
EGF or TGF-α.
3. Deletion in the C-terminus of the receptor that prevents downregulation of the 
receptor after ligand binding.
In human oral carcinogenesis EGFR is overexpressed as this gene is amplified. 
Therefore, it has been identified that in comparison to the normal counterpart, 
malignant oral keratinocytes possess 5–50 times more EGF receptor. Moreover, in 
oral carcinogenesis the mechanism of signal transduction is either because of over-
expression of normal receptors due to mutated gene or because of the formation of 
many new receptors is not understood yet. Henceforth, oral tumors, having EGFR 
overexpression, have been shown to exhibit a higher response to chemotherapy than 
EGFR-negative tumors, presumably because of higher intrinsic proliferative activity 
leading to higher sensitivity to cytotoxic drugs [6].
3.3 Intracellular signal transduction pathways (RAS)
Like growth factor receptors, intracellular messengers can be intrinsically activated, 
thereby delivering a continuous rather than a ligand-regulated signal [6]. An oncogene 
can be activated either by gene amplification and/or mutation. In OSCC, the ras is one 
of the most frequently genetically altered oncogene. The mutations of three isoforms 
of ras gene such as Hras, Kras and Nras produce the same phenotype in the in vitro 
transformation assays. Mutations of the Hras appear to be highly prevalent in OSCC 
when compared to the Kras and Nras have been reported approximately from 0 to 55%.
3.3.1 Mechanism of ras activation
These genes encode closely related proteins that are located on the cytoplasmic 
side of the cell membrane and transmit messages from the cell surface receptors to 
intracellular regulatory enzymes [6].
RAS present on the cytoplasmic side of cell membrane get activated by growth 
factors through enhanced exchange of guanine nucleotide by forming Grb2 SOS 
complex. The molecular mechanism underlying in the functions activation of ras 
depends on the whole super family of small G-proteins because there exist a switch 
between GTP bound active and GDP-bound inactive state [10].
In normal human cell, an equilibrium is strictly maintained by the activity of 
GAPs (GTPase activating proteins) and GEFs (Guanine nucleotide exchange fac-
tors) between the active and inactive state because ras proteins have a minimal and 
a measurable activity on their own. The GAPs accelerate the GTP hydrolysis of ras 
and the antagonist GEFs such as ras-GRFs and ras-GRPs catalyze and weakens the 
GDP replacing with GTP. In a cell where ras is mutated, the equilibrium between the 
GTP and GDP-bound state is impaired. The ras is mutated predominantly at codon 
G12, G13 and Q61. In K-RAS and H-RAS because of point mutations GAP catalyzed 
hydrolysis of GTP to GDP, thereby generate constantly active ras and is responsible 
for the activation of downstream effectors whereby cell undergoes aberrant mal-
functioning leading to malignancy (Figure 4) [10].
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3.3.2 Ras and its major signaling pathways
The ras oncogenes are associated with proteins that are involved in the trans-
duction of extracellular growth, differentiation and survival signals. Ras activate 
receptor tyrosine kinases (RTKs), which further activate two key signal transduc-
tion components:
1. Small GTPase
2. Lipid kinase PI(3)K.
The activated ras stimulates mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol-3-kinase (PI3K)/Akt pathways. The key downstream steps 
involve phosphorylation by RAF1 kinase on two distinct serine residues MEK1/2. 
The MEK1/2 further phosphorylates specific threonine and tyrosine residues in the 
activation loops of ERK1/2 and leads to growth and differentiation. On the other 
hand ras transduces PI3K/Akt signaling pathway which lead to cell cycle prolifera-
tion and survival [10].
3.4 DNA binding nuclear proteins transcription factors (MYC, FOS, JUN)
Transcription factors, or proteins that stimulate other genes to be activated, 
are also altered in oral cancer. A growing number of the known proto-oncogenes 
encode nuclear proteins. These nuclear proteins are further regulated by recep-
tor activated second messenger pathways. Neutralization of these encoded genes 
result in cell cycle arrest which prevents mitogenic and differentiation responses to 
growth factors. C-myc is a gene which helps regulate cell proliferation and apoptosis 
and is frequently overexpressed in oral cancers as a result of gene amplification. 
Figure 4. 
Mechanisms of the ras activation.
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C-myc is often overexpressed in poorly differentiated tumors, although more 
recently c-myc has been shown to be overexpressed in moderate and well differenti-
ated oral carcinomas, in which cell proliferation far outweighed the number of 
apoptotic cells present. For apoptosis, c-myc requires p53 for regulating cell prolif-
eration. c-Myc interacts with retinoblastoma tumor suppressor gene Rb-1 nuclear 
protein pR6, preventing its transcription, and thus inhibiting cell proliferation. 
However, on phosphorylation of pR6, c-Myc is increased and cell proliferation pro-
ceeds. Another transcription factor which is also amplified in head and neck cancers 
is PRADl (also CCNDl or cyclin Dl) which acts too as a cell cycle promoter [5–6, 8].
Particular order of oncogene activation has not been shown in oral cancers; 
instead the accumulation of activated oncogenes should be of primary importance. 
The importance of the currently identified oncoproteins to oral carcinogenesis is 
under investigation. Other oncogenes linked to oral cancer development are hst-1, 
k-2, bcl-1, sea, men-1, and eM1s-1.3.4. Oncogenes alone, however. Not sufficient to 
result in oral cancer but appear to be initiators of the process and should work along 
with the inactivation of tumor suppressor genes. The critical event in the transfor-
mation of a “premalignant” cell to a malignant cell is the inactivation of cellular 
negative regulators, tumor suppressor genes.
3.5 Cell cycle proteins (cyclins and cyclin dependent protein kinases)
The cell cycle is a mammalian cells proliferation regulation process and has 4 
functional phases:
a. S phase (DNA replication)
b. G2 phase (cells prepare for mitosis)
c. M phase (DNA and cellular components division into two daughter cells)
d. G1 phase (cells commit and prepare for another round of replication).
S and M phases are the major and common process in all cell cycles for replica-
tion of cells. It requires interplay of expression of cyclins and cyclin dependent 
kinases in response to growth factors.
3.5.1 Cdks, the cell cycle
Cdk2 and cdk1, together, direct S and G2 phase transit, while cdk1 governs the 
G2/M transition and mitotic progression. Cdks can be divided into two groups:
a. ‘Cell cycle’ cdks, which orchestrate cell cycle progression.
b. ‘Transcriptional’ cdks, which contribute to mRNA synthesis and processing.
The first group encompasses cyclin D-cdk4 and 6, as well as cyclin E-cdk2 
complexes, which sequentially phosphorylate the retinoblastoma protein (RB), to 
facilitate the G1/S transition. Cyclin A-cdk 2 and 1 are required for orderly S phase 
progression, whereas cyclin B-cdk1 complexes control the G2/M transition and 
participate in mitotic progression [11].
The second group includes cyclin H-cdk7 and cyclin T-cdk9 (pTEFb). It phos-
phorylates the carboxy-terminal domain of RNA polymerase II to promote elonga-
tion of mRNA transcription. Cyclin T-cdk9 also regulates mRNA processing [12].
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3.5.2 Cdk’s and cancer
CDK’s and cyclins are the biochemicals play a pivotal role in cell cycle progression 
and transcription. Errors and dysregulation like amplification, mutation, deletion and 
hypermethylation of cyclins and its cdk partners activity results in loss of cell cycle check 
points and apoptotic activity which is a major cause for proliferative disorders such as 
cancer and which has been directly linked to the molecular pathology of cancer [11].
Cell cycle progression through the G1 phase is regulated by the action of cyclin 
D-cdk4, cyclin D-cdk6, and cyclin E-cdk2. This transition is mediated through the RB, 
which is regulated through sequential phosphorylations by CDK. Various genetic and 
epigenetic alterations in human cancer including mutations and amplification of Cdk 
and positive regulatory Cyclin subunits, lead to a hyperactivation of Cdk regulatory 
pathways. Henceforth, alteration in cell cycle checkpoints causes abnormal cell prolif-
eration and results in tumor progression. Although mutations of cdk genes in tumor 
cells are rather infrequent with the exception of Cdk4 and Cdk6 amplification, overex-
pression or hyperactivation of basic cell cycle regulators is a general feature of human 
tumors like leukemia or carcinomas and were associated with poor prognosis [11].
3.6 Inhibitors of apoptosis (Bcl-2)
Apoptosis “programmed cell death’—is a physiologic process of cell to undergo 
death following sequence of events once the function is over. Any alterations in the 
mechanism of cell undergoing apoptosis not only contribute to abnormal prolifera-
tion of cell but also enhance resistance to anticancer therapies, such as radiation 
and cytotoxic agents. One of the suggested mechanisms for developing resistance to 
cytotoxic antineoplastic drugs is the alteration in expression of B-cell lymphoma-2 
(Bcl-2) family members.
A balance between newly forming cells and old dying cells is maintained by 
Bcl-2 family of proteins which consists of 25 pro- and anti-apoptotic members. 
When there is alteration or disbalance in ratio of distribution of pro and anti-
apoptotic proteins resulting in the overexpression of anti-apoptotic Bcl-2 family 
members, apoptotic cell death can be prevented. Targeting the anti-apoptotic Bcl-2 
family of proteins can improve apoptosis and thus overcome drug resistance to 
cancer chemotherapy [6].
Two major pathways of apoptosis are the intrinsic and extrinsic cell-death 
pathways.
The intrinsic cell death pathway/mitochondrial apoptotic pathway: mainly trig-
gers apoptosis in response to internal stimuli and is activated by a wide range of sig-
nals, including radiation, cytotoxic drugs, cellular stress, DNA damage and growth 
factor withdrawal. This mechanism involves the release of proteins cytochrome c 
from the mitochondrial membrane space which in turn activates pro caspase-9 and 
induces apoptosis.
The extrinsic cell-death pathway: pathway functions independently of mito-
chondria and executes cascade activation of caspases. Activation of cell-surface 
death receptors, such as Fas and tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) receptors, directly activate the caspase cascade via an “initiator” 
caspase (caspase-8) the role of which is to cleave other pro-caspases into active 
“executioner” caspases which induces degradation of cytoskeleton and nucleus [13].
3.6.1 Role of Bcl-2 in oral carcinogenesis
Bcl-2 family members can be divided into three subfamilies based on structural 
and functional features [13].
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1. Bcl-2 homology—the anti-apoptotic subfamily contains the Bcl-2, Bcl-XL, 
Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B proteins, which suppress apoptosis and 
contain all four Bcl-2 homology domains.
2. Multidomain proteins—some pro-apoptotic proteins, such as Bax, Bak, and 
Bok, contain Bcl-2 homology domains.
3. BH3-only proteins—pro-apoptotic proteins, such as Bim, Bad, and Bid, 
contain only the BH3 domain.
Recent studies have shown that Bcl-2 expression is upregulated in oral 
SCC. Bcl-2 inhibits cell death via inhibiting apoptosis. Hence, Bcl-2-mediated 
inhibition of apoptosis may be an important factor in the pathogenesis of oral 
SCC. Bax forms heterodimers with Bcl-2 and when present in excess, Bax overrides 
the anti-apoptotic activity of Bcl-2.
P53 tumor-suppressor protein is a direct transcriptional activator of the human 
Bax gene suggesting that p53 may, in some instances, induce apoptosis via Bax-
mediated suppression of Bcl-2 activity. In mutagenesis experiments, single amino 
acid substitutions in Bcl-2 homology domains disrupted Bcl-2-Bax heterodimers. 
The Bcl-2 mutants that failed to complex with Bax could no longer inhibit apopto-
sis. According to the study done by Oltvai et al. (1993) it was suggested that anti-
apoptotic activity of Bcl-2 was inhibited by Bax, whereas the findings of Yin et al. 
(1994) is converse to that of the previous findings, i.e. that the function of Bcl-2 
is to inhibit the apoptotic activity of Bax. But it was further hypothesized that the 
possible mechanism was the formation of Bcl-2-Bax heterodimers which inhibits 
both apoptotic and anti-apoptotic activity and is only seen when there is a func-
tional excess of Bax or Bcl-2, respectively.
Bcl-x and Bcl-2 form heterodimers with Bad. This dimerization displaces Bax 
from Bcl-x, and Bcl-2 thereby enhances apoptosis. Therefore, the Bcl-2 family of 
related proteins (as with the Myc family) functions in part through protein-protein 
interactions.
In conclusion, Bcl-2-mediated inhibition of apoptosis may be an important fac-
tor in the pathogenesis of oral SCC. Furthermore, by blocking apoptosis, Bcl-2 can 
increase tumor cell resistance to anti-neoplastic drugs.
4. Tumor suppressor genes
Genes that encode the proteins for negative signal transduction pathways and 
modulate excitatory pathways and negate their effect in a “checks and balances” 
have been called as growth regulatory genes, recessive oncogenes or anti-oncogenes, 
but they are most often referred to as tumor suppressor genes. Negative regulatory 
pathways allow the cell to perform its function in the face of changing internal and 
external stresses [1, 14].
As been mentioned earlier in the chapter “Oncogenes alone are not sufficient to 
cause oral cancer and appear to be initiators of the process”.
The transformation of a premalignant cell to a malignant cell is due to the inacti-
vation of tumor suppressor gene which is a major event leading to the development 
of malignancy.
This mechanism of inactivation is may be due to point mutations, deletions, 
hypermethylation and rearrangements in gene copies. It was identified that many 
tumor suppressor genes were initially identified in pediatric tumors that formed 
early in life because one mutated tumor suppressor gene was inherited [1].
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This mechanism led the evolution of “Knudson two hit hypothesis” This theory 
suggested a genetic model for retinoblastoma development. According to this RB gene 
mutation is inherited is described as the first hit and the tumor-restricted mutation as 
the second hit. This model further includes genetic aberrations, such as inactivation 
of a tumor suppressor and activation of an oncogene, as hits. Currently an extensive 
research on “chromosomal walking” is highlighted in pediatric tumors were the first 
tumor suppressor genes isolated with large chromosomal alterations. Therefore, 
although the identification of these “cancer genes” is one of the primary focuses of 
molecular biologists today, still far less is known about tumor suppressor genes [1].
4.1 Function of p53 as a tumor suppressor gene
The many roles of p53 as a tumor suppressor include the ability to induce cell 
cycle arrest, DNA repair, senescence, and apoptosis. Due to many genotoxic or 
chemical insults when genomic DNA damage is being identified, p53 gene activated 
and stop cell to divide further at the G1-S boundary and it repairs rather than 
replicates the error in the genetic code. If the chromosomal damage is too great, p53 
gene activate apoptotic pathways [15].
4.2 Mutant form of p53
Mutation of p53 allows tumors to pass through the G1-S boundary and propagate 
the genetic alterations that may lead to other activated oncogenes or inactivated tumor 
suppressor genes. In addition to the loss of function that a mutation in TP53 may cause, 
many p53 mutants are able to actively promote tumor development by other means like:
1. Dominant negative manner
2. Gain of function
4.2.1 Dominant negative manner
In a heterozygous situation, where both wildtype (WT) and mutant alleles exist, 
mutant p53 can antagonize the activity of WT p53 tumor suppressor functions in a 
dominant negative (DN) manner. The transcriptional activity of WT p53 depends 
on forming tetramer where mutant p53 interfered in DNA binding activity of WT 
p53. However, such a heterozygous state is often transient, as TP53 mutations are 
frequently followed by loss of heterozygosity (LOH) during cancer progression as 
WT p53 allele is either deleted or mutated [14].
4.2.2 Gain of function
This term refers to the acquisition of oncogenic properties by the mutant form 
of p53 protein, compared with the mere inactivation of the protein. During tumori-
genesis both the dominant negative and GOF effects may play a significant role in 
missense mutations of TP53 protein [15].
4.3 Mechanistic views of how mutant p53 exerts its function
Various mechanisms by which mutant p53 works in tumor progression:
1. GOF properties acquired by mutant p53 drive cells toward migration, inva-
sion, and metastasis. Recent work demonstrates that mutant p53 can augment 
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cell migration and invasion. It was studied that “oncogenic” Ras and “Tumor 
Suppressor” mutant p53 activities occurs in early neoplasms to promote 
growth and survival, they play an equally important role at late stages of tumor 
progression in empowering TGFβ-induced metastasis.
2. EMT—metastasis follow the properties of epithelial to-mesenchymal transi-
tion (EMT), including loss of cell-cell adhesion and an increase in cell motil-
ity., Mutant p53 was found to promote EMT by facilitating the function of the 
key transcriptional regulators of this process, TWIST1 and SLUG whereas WT 
p53 was shown to inhibit EMT mechanism.
3. Tp63—an additional mechanism through which mutant p53 was shown to aug-
ment cell invasion is via the inhibition of transcriptional activity of TAp63α, 
but is unable to inhibit this function of TAp63γ indicating a protooncogenic 
activity of TP 53 [14].
It appears that in certain cancers, p53 is mutated late in the tumorigenesis 
process or plays a significant role in those advanced stages, whereas other stud-
ies indicates its expression in early stages of tumor progression. Therefore, it 
was hypothesized that TP53 mutations at early stages of tumorigenesis results in 
uncontrolled proliferation, a feature of both benign and malignant tumors, whereas 
mutations at later stages synergize with additional oncogenic events to drive inva-
sion and metastasis, the hallmark of malignant tumors. p53 inactivation as a single 
event results in the high proliferation rate. Inactivation of p53 in conjunction with 
oncogenic H-Ras expression activates the expression of a large set of chemokines 
and interleukins reported to promote angiogenesis, invasion, and metastasis.
In general, tumor suppressor genes are thought to act recessively so that both 
copies of the gene must be inactivated for malignancy to occur. LOH and p53 
mutations have been reported in several tumors. There is also controversy about 
the relation between mutated p53 and detection of its expression by immunohisto-
chemistry. Some authors have commented on high correlation between p53 expres-
sion and point missense mutation, whereas others have reported discrepancy in oral 
cancer and lack of expression of p53 as immunocytochemistry have been attributed 
to insensitive methods of detecting p53 mutation. In Li-Fraumeni syndrome, 
mutant p53 is unstable, like the wild-type p53 protein, which suggests that some 
other event may be necessary for stability, and that stability of p53 is not intrinsic 
to the mutant p53 structure but might vary in different cell backgrounds. This 
mechanism can be highlighted by p53 and mdm2 relation because when normal p53 
is bound to mdm2 it is targeted for destruction by the ubiquitin dependent pathway. 
However, it appears that mutant p53 fails to stimulate transcription of mdm2 and 
therefore mutant p53 is not degraded. Another mechanism tells that if E6 protein 
forms complexes with wild-type p53 and promotes p53 degradation this could 
account for the lack of concordance between p53 mutation frequency and LOH [16].
Other tumor suppressor genes include doc-1, the retinoblastoma gene, and APC.
5. Role of HPV in pathogenesis of OSCC
The role of HPV in pathogenesis of human malignancies has become convinc-
ingly established. HPV is a strictly epitheliotropic, circular double-stranded DNA 
virus that is known to be the primary cause of cervical cancer and currently estab-
lishing important role in oral carcinogenesis. There are more than 100 subtypes of 
HPV, some of which are involved in oral carcinogenesis and have been designated as 
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high-risk HPVs. Approximately 85% of squamous cell carcinoma patients. The viral 
DNA gets incorporated into the host genome and is responsible for malignant trans-
formation. The virus contains two oncogenes, E6 and E7, E1 and E2 open reading 
Figure 5. 
Cell cycle deregulation by human papilloma virus activated by E6 and E7.
Figure 6. 
Proposed molecular model for the genetic events in squamous cell carcinoma of the head and neck [19, 20].
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frames will be interrupted and can lead to overexpression of E6 and E7 proteins. 
This E7 protein binds to underphosphorylated form of retinoblastoma results in 
the enhanced phosphorylation and degradation. Degraded form of pRb displaces 
E2F form of transcription factor and subsequent activation of gene promoting cell 
proliferation. E6 protein degrades p53 protein causing perturbation of cell cycle 
regulation in the infected cells which is considered to be the onset of HPV-mediated 
carcinogenesis. The virus is not easily cultured, therefore determining the role of 
virus in pathogenesis of OSCC is usually determined by detection of the viral DNA 
genome or expression of the viral genes using PCR methods. E6 and E7 have a 
crucial role in cervical cancer were also involved in HPV mediated carcinogenesis of 
the upper aerodigestive tract (Figures 5 and 6) [9, 17, 18].
6. Conclusions
Cellular signaling pathways are not isolated from each other but are intercon-
nected to form complex signaling networks. Any change or diversification in this 
cellular signaling network such as increased production of growth factor or cell 
surface receptors, increase transcription or translation or intracellular messenger 
levels will give rise to abnormal proliferation of cell and is one of the reason for 
multifactorial oral carcinogenesis These changes can, in turn, cause a activation of 
protooncogene or loss of tumor suppressor activity which give rise to a phenotype 
capable of increasing cellular proliferation, weakening cell cohesion, and causing 
local infiltration and metastasis.
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